Asmanex approved for adult asthma in Japan
This article was originally published in Scrip
Schering-Plough's once-daily inhaled corticosteroid Asmanex (mometasone furoate) has been approved in Japan. The dry powder product is delivered through the breath-activated Twisthaler system and indicated for the treatment of adult bronchial asthma.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.